Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: enhanced tumour infiltrating lymphocytes - AgonOx/SQZ Biotech

Drug Profile

Research programme: enhanced tumour infiltrating lymphocytes - AgonOx/SQZ Biotech

Alternative Names: mRNA engineered tumour infiltrating lymphocytes - SQZ Biotech; SQZ® TILs; TIL - SQZ Biotech

Latest Information Update: 14 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AgonOx; SQZ Biotech
  • Class Antineoplastics; Immunotherapies; Tumour infiltrating lymphocyte therapies
  • Mechanism of Action Immunologic cytotoxicity; Interleukin 12 replacements; Interleukin-2 replacements; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Malignant melanoma

Most Recent Events

  • 13 Sep 2022 Preclinical pharmacodynamic data presented at the European Society for Medical Oncology (ESMO-2022)
  • 30 Nov 2021 Enhanced tumour infiltrating lymphocytes - SQZ Biotech is available for licensing as of 30 Nov 2021. https://sqzbiotech.com/work-at-sqz/#contact-us
  • 10 Nov 2021 Preclinical trials in Cancer in USA (Parenteral) as of November 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top